Gonadorelin Acetate 2mg

Gonadorelin is native GnRH -- the same sequence as the endogenous hormone. It has a short half-life (minutes) and is studied for stimulating LH and FSH in a pulsatile manner in research models. GnRH agonists like triptorelin, leuprolide, and goserelin are modified analogues with much longer half-lives. Paradoxically, continuous exposure to long-acting GnRH agonists desensitizes GnRH receptors, initially associated with a hormone surge followed by suppression of LH and FSH -- the mechanism studied in hormone-sensitive cancer and endometriosis research models. Gonadorelin's short half-life means it stimulates rather than suppresses when dosed intermittently in these models.

The GnRH stimulation paradigm (also called the GnRH or LHRH challenge) assesses pituitary responsiveness by measuring LH and FSH response to an injection of gonadorelin in research models. Samples are taken before and at 30 and 60 minutes after injection. A robust LH and FSH rise indicates intact pituitary responsiveness in the model; a blunted or absent response indicates reduced pituitary response. The paradigm is used in research to distinguish hypothalamic from pituitary contributions to the HPG axis -- helping determine whether the limiting factor is inadequate GnRH signal or inadequate pituitary response to that signal.

GnRH receptor signaling is frequency-encoded. In research models, the pituitary responds differently to different GnRH pulse frequencies: optimal pulsatility (roughly 1 pulse per 90-120 minutes) is associated with maintained LH and FSH secretion. Faster pulses shift the ratio toward LH; slower pulses favor FSH. Continuous stimulation desensitizes the receptor entirely and is associated with suppressed gonadotropin secretion. This frequency sensitivity is why pulsatile GnRH delivery is studied for restoring gonadotropin output in research models of hypothalamic hypogonadism, while continuous GnRH agonist exposure suppresses it -- opposite outcomes from the same receptor in these models.